Perimeter Medical Imaging AI Announces Follow-On Commercial Placement of Perimeter S-Series OCT within National Healthcare Provider System at New Hospital Site
November 15 2022 - 8:30AM
Business Wire
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF)
(FSE: 4PC) announced another commercial placement of its flagship
Perimeter S-Series OCT system at a second hospital within one of
the largest healthcare networks in North Texas, which is part of a
major national healthcare system. Perimeter is a medical technology
company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
high unmet medical needs.
Jeremy Sobotta, Perimeter’s Chief Executive Officer stated,
“Approximately six weeks ago, we announced the commercial placement
of our Perimeter S-Series OCT system within a national healthcare
network. I am pleased to report that we have now completed the
second commercial installation at another hospital within this
major healthcare system. This further validates a core part of our
commercial strategy as we expand use within key integrated delivery
network customers. Further, we are receiving timely, positive
feedback that the value provided by our technology is resonating
with not only our end-users but other stakeholders within the
healthcare system as well.”
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level, with 10x greater image resolution than X-ray and ultrasound,
and 100x greater than MRI. The breakthrough-device-designated
investigational Perimeter B-Series OCT with ImgAssist AI represents
our next-generation artificial intelligence technology that is
currently being evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million awarded by the Cancer
Prevention and Research Institute of Texas. The company’s ticker
symbol “PINK” is a reference to the pink ribbons displayed during
Breast Cancer Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist; Perimeter’s expected development activities and the
expected details regarding Perimeter’s ongoing clinical trials are
forward-looking information. Forward-looking statements should not
be read as guarantees of future performance or results, and will
not necessarily be accurate indications of whether, or the times at
or by which, any particular result will be achieved. No assurance
can be given that any events anticipated by the forward-looking
information will transpire or occur. Forward-looking information is
based on information available at the time and/or management’s
good-faith belief with respect to future events and are subject to
known or unknown risks, uncertainties, assumptions, and other
unpredictable factors, many of which are beyond Perimeter’s
control. Such forward-looking statements reflect Perimeter’s
current view with respect to future events, but are inherently
subject to significant medical, scientific, business, economic,
competitive, political, and social uncertainties and contingencies.
In making forward-looking statements, Perimeter may make various
material assumptions, including but not limited to (i) the accuracy
of Perimeter’s financial projections; (ii) obtaining positive
results from trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market, and economic
conditions. Further risks, uncertainties and assumptions include,
but are not limited to, those applicable to Perimeter and described
in Perimeter’s Management Discussion and Analysis for the year
ended December 31, 2021, which is available on Perimeter’s SEDAR
profile at www.sedar.com, and could cause actual events or results
to differ materially from those projected in any forward-looking
statements. Perimeter does not intend, nor does Perimeter undertake
any obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221115005614/en/
Chris Scott Chief Financial Officer Perimeter Medical Imaging
AI, Inc. Investors: investors@perimetermed.com Toll-free:
888-988-7465 (PINK) Jodi Regts Corporate Communications Perimeter
Medical Imaging AI, Inc. Media: media@perimetermed.com Mobile:
469-743-1834
Simplify Exchang (NYSE:PINK)
Historical Stock Chart
From Oct 2024 to Nov 2024
Simplify Exchang (NYSE:PINK)
Historical Stock Chart
From Nov 2023 to Nov 2024